Face Name Associative Memory Exam and biomarker status in the ARMADA study: Advancing reliable measurement in Alzheimer's disease and cognitive aging
Abstract The Face Name Associative Memory Exam (FNAME) was introduced into the NIH Toolbox as part of the ARMADA study and establishes normative data for diverse participants, ages 64 to 85+, and proposes cutoff scores between biomarker positive versus negative (+/−) groups. The FNAME was administer...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-07-01
|
| Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/dad2.12473 |
| _version_ | 1797672419588046848 |
|---|---|
| author | Dorene M. Rentz Hannah M. Klinger Aubryn Samaroo Colleen Fitzpatrick Olivia R. Schneider Saki Amagai John Devin Peipert |
| author_facet | Dorene M. Rentz Hannah M. Klinger Aubryn Samaroo Colleen Fitzpatrick Olivia R. Schneider Saki Amagai John Devin Peipert |
| author_sort | Dorene M. Rentz |
| collection | DOAJ |
| description | Abstract The Face Name Associative Memory Exam (FNAME) was introduced into the NIH Toolbox as part of the ARMADA study and establishes normative data for diverse participants, ages 64 to 85+, and proposes cutoff scores between biomarker positive versus negative (+/−) groups. The FNAME was administered to 257 participants across the clinical spectrum with 122 having amyloid biomarkers. Linear regression explored the association between demographics and FNAME and between amyloid (+/−) groups. Receiver operating characteristic curves (ROC) identified performance thresholds that best discriminated between biomarker (+/−) individuals. Lower FNAME scores occurred in males, older ages, Black/African Americans, Hispanics, and biomarker‐positive participants. ROC analyses demonstrated acceptable accuracy (0.73 to 0.77) but only when combined with clinical status. The diagnostic discrimination of amyloid positivity was acceptable but not excellent, suggesting the FNAME may be a better screening indicator of clinical status rather than amyloid deposition in cognitively normal individuals. Normative data are provided. |
| first_indexed | 2024-03-11T21:29:46Z |
| format | Article |
| id | doaj.art-4def25d74ed34b009e1e1dfdacec61c3 |
| institution | Directory Open Access Journal |
| issn | 2352-8729 |
| language | English |
| last_indexed | 2024-03-11T21:29:46Z |
| publishDate | 2023-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| spelling | doaj.art-4def25d74ed34b009e1e1dfdacec61c32023-09-27T11:20:33ZengWileyAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring2352-87292023-07-01153n/an/a10.1002/dad2.12473Face Name Associative Memory Exam and biomarker status in the ARMADA study: Advancing reliable measurement in Alzheimer's disease and cognitive agingDorene M. Rentz0Hannah M. Klinger1Aubryn Samaroo2Colleen Fitzpatrick3Olivia R. Schneider4Saki Amagai5John Devin Peipert6Departments of Neurology Massachusetts General Hospital Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USADepartments of Neurology Massachusetts General Hospital Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USAPraxis Precision Medicines Boston Massachusetts USADepartments of Neurology Massachusetts General Hospital Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USAAlbany Medical College Albany New York USANorthwestern University Feinberg School of Medicine Chicago Illinois USANorthwestern University Feinberg School of Medicine Chicago Illinois USAAbstract The Face Name Associative Memory Exam (FNAME) was introduced into the NIH Toolbox as part of the ARMADA study and establishes normative data for diverse participants, ages 64 to 85+, and proposes cutoff scores between biomarker positive versus negative (+/−) groups. The FNAME was administered to 257 participants across the clinical spectrum with 122 having amyloid biomarkers. Linear regression explored the association between demographics and FNAME and between amyloid (+/−) groups. Receiver operating characteristic curves (ROC) identified performance thresholds that best discriminated between biomarker (+/−) individuals. Lower FNAME scores occurred in males, older ages, Black/African Americans, Hispanics, and biomarker‐positive participants. ROC analyses demonstrated acceptable accuracy (0.73 to 0.77) but only when combined with clinical status. The diagnostic discrimination of amyloid positivity was acceptable but not excellent, suggesting the FNAME may be a better screening indicator of clinical status rather than amyloid deposition in cognitively normal individuals. Normative data are provided.https://doi.org/10.1002/dad2.12473Alzheimer's diseasecognitiondementiamild cognitive impairmentneuropsychologyNIH Toolbox |
| spellingShingle | Dorene M. Rentz Hannah M. Klinger Aubryn Samaroo Colleen Fitzpatrick Olivia R. Schneider Saki Amagai John Devin Peipert Face Name Associative Memory Exam and biomarker status in the ARMADA study: Advancing reliable measurement in Alzheimer's disease and cognitive aging Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring Alzheimer's disease cognition dementia mild cognitive impairment neuropsychology NIH Toolbox |
| title | Face Name Associative Memory Exam and biomarker status in the ARMADA study: Advancing reliable measurement in Alzheimer's disease and cognitive aging |
| title_full | Face Name Associative Memory Exam and biomarker status in the ARMADA study: Advancing reliable measurement in Alzheimer's disease and cognitive aging |
| title_fullStr | Face Name Associative Memory Exam and biomarker status in the ARMADA study: Advancing reliable measurement in Alzheimer's disease and cognitive aging |
| title_full_unstemmed | Face Name Associative Memory Exam and biomarker status in the ARMADA study: Advancing reliable measurement in Alzheimer's disease and cognitive aging |
| title_short | Face Name Associative Memory Exam and biomarker status in the ARMADA study: Advancing reliable measurement in Alzheimer's disease and cognitive aging |
| title_sort | face name associative memory exam and biomarker status in the armada study advancing reliable measurement in alzheimer s disease and cognitive aging |
| topic | Alzheimer's disease cognition dementia mild cognitive impairment neuropsychology NIH Toolbox |
| url | https://doi.org/10.1002/dad2.12473 |
| work_keys_str_mv | AT dorenemrentz facenameassociativememoryexamandbiomarkerstatusinthearmadastudyadvancingreliablemeasurementinalzheimersdiseaseandcognitiveaging AT hannahmklinger facenameassociativememoryexamandbiomarkerstatusinthearmadastudyadvancingreliablemeasurementinalzheimersdiseaseandcognitiveaging AT aubrynsamaroo facenameassociativememoryexamandbiomarkerstatusinthearmadastudyadvancingreliablemeasurementinalzheimersdiseaseandcognitiveaging AT colleenfitzpatrick facenameassociativememoryexamandbiomarkerstatusinthearmadastudyadvancingreliablemeasurementinalzheimersdiseaseandcognitiveaging AT oliviarschneider facenameassociativememoryexamandbiomarkerstatusinthearmadastudyadvancingreliablemeasurementinalzheimersdiseaseandcognitiveaging AT sakiamagai facenameassociativememoryexamandbiomarkerstatusinthearmadastudyadvancingreliablemeasurementinalzheimersdiseaseandcognitiveaging AT johndevinpeipert facenameassociativememoryexamandbiomarkerstatusinthearmadastudyadvancingreliablemeasurementinalzheimersdiseaseandcognitiveaging |